期刊文献+

外周T细胞淋巴瘤临床特点及疗效分析117例 被引量:4

下载PDF
导出
摘要 目的:分析外周T细胞淋巴瘤(peripheral T-cell lymphomas,PTCLs)的临床特点、治疗效果及影响预后的因素。方法:回顾性分析2005-2012年南方医院收治的117例PTCLs患者的临床资料,采用KaplanMeier法及Cox比例风险模型进行生存及预后因素分析。结果 :PTCLs亚型中常见的有结外NK/T细胞淋巴瘤(ENKL)、外周T细胞淋巴瘤-非特指型(PTCL-NOS)、血管免疫母细胞淋巴瘤(AITL)和间变性大细胞淋巴瘤(ALCL)。PTCLs中位发病年龄42岁,初治时40例接受CHOP方案化疗,77例接受高强度方案化疗。33例初治时接受局部放疗联合化学治疗。9例接受自体或异基因造血干细胞移植。单因素分析提示高强度化疗、放化疗联合治疗可以提高OS及PFS。多因素分析提示LDH水平升高、ECOG评分高(PS>1)、Ann ArborⅢ/Ⅳ期为OS独立预后不良因素,高强度化疗、放化疗联合治疗可提高PFS。结论 :LDH、体能状态、Ann Arbor分期为PTCLs重要的独立预后因素,初治时接受高强度化疗或放化疗联合治疗对患者OS无显著影响,但能改善PFS。
出处 《实用医学杂志》 CAS 北大核心 2015年第10期1679-1681,共3页 The Journal of Practical Medicine
基金 国防科工委课题分课题(编号:B3320062101)
  • 相关文献

参考文献9

  • 1Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008 : an overview [J]. Pathologica,2010, 102(3): 83-87.
  • 2Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases [J]. Clin Microbiol Rev,2010, 23 (3): 577-589.
  • 3Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents [J]. Blood, 2009, 114(23): 4771-4776.
  • 4Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-ceil and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group [J]. Blood, 2010, 116(18) : 3418-3425.
  • 5Jantunen E, Siitonen T, Putkonen M, et al. Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey [J]. Leuk Lymphoma,2004, 45 (12): 2485-2489.
  • 6D'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-OI[J]. J Clin Oncol,2012, 30(25): 3093- 3099.
  • 7Broussais-Guillaumo F, Coso D, Belmecheri N, et al. Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution [J]. Leuk Lymphoma, 2013, 54( 11 ) : 2392-2398.
  • 8Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy [J]. J Chn Oncol,2012, 30(6): 631-636.
  • 9Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin [J]. Blood,2014, 123(20) : 3095-3100.

同被引文献21

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部